Immunogenetics of Graves' disease - An overview

被引:0
|
作者
Manfras, BJ [1 ]
Kunl, P [1 ]
Semana, G [1 ]
Boehm, BO [1 ]
机构
[1] Univ Ulm, Dept Med, D-89081 Ulm, Germany
关键词
D O I
暂无
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Autoimmune thyroiditis, considered the prototype autoimmune organ-specific disease, was the first disease described with so called organ-specific autoantibodies. Graves' disease (GD) as a, member of this group, is characterized not only by its association with other organ-specific autoimmune diseases but also by a female preponderance, association with HLA-alleles, lymphocytic infiltration of the target organ, and tile evidence of immune system activation, particularly during the active phase of disease when autoantibodies and activated T-cells are present in the circulation. The clinical manifestation of GD by the signs and symptoms of thyrotoxicosis is due to the presence of TSH-receptor stimulating autoantibodies, thus leading to stimulation of thyroid function. GD is characterised by a heterogeneous clinical presentation, i.e. presence or absence of endocrine ophthalmopathy. Studies of association between clinical features of GD with markers within the HLA-lacus were a component of the recent 12th International Histocompatibility Workshop and Conference. Through this international collaboration more than five hundred patients with GD were analysed, The major aim was to determine whether some particular HLA markers may discriminate different forms of the disease. A genetic predisposition has been recognised in case-control-studies and in family-studies. Numerous subsequent studies have shown association of GD with genetic markers mainly within the HLA-locus. The following article is divided into two parts, the first part gives an overview of the clinical and immunological characteristics of GD, while the second part summarises at least partially the results of the International Histocompatibility Workshop GD study, respectively.
引用
收藏
页码:71 / 86
页数:16
相关论文
共 50 条
  • [41] The immunogenetics of inflammatory bowel disease -: Discussion
    Pajares
    López-Nava
    DRUGS OF TODAY, 2001, 37 : 261 - 261
  • [42] Poster Group 9 - Immunogenetics of Disease
    Genes & Immunity, 2003, 4 (Suppl 1): : S32 - S45
  • [43] Management of Graves' Disease An Overview and Comparison of Clinical Practice Guidelines with Actual Practice Trends
    Muldoon, Becky T.
    Mai, Vinh Q.
    Burch, Henry B.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2014, 43 (02) : 495 - +
  • [44] Graves’ disease
    Terry F. Davies
    Stig Andersen
    Rauf Latif
    Yuji Nagayama
    Giuseppe Barbesino
    Maria Brito
    Anja K. Eckstein
    Alex Stagnaro-Green
    George J. Kahaly
    Nature Reviews Disease Primers, 6
  • [45] Graves Disease
    Armys, Melda Deliana
    HORMONE RESEARCH, 2008, 70 : 61 - 61
  • [46] Graves' Disease
    Kahaly, George J.
    Olivo, Paul D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (02): : 184 - 184
  • [47] Graves' disease
    Davies, Terry F.
    Andersen, Stig
    Latif, Rauf
    Nagayama, Yuji
    Barbesino, Giuseppe
    Brito, Maria
    Eckstein, Anja K.
    Stagnaro-Green, Alex
    Kahaly, George J.
    NATURE REVIEWS DISEASE PRIMERS, 2020, 6 (01)
  • [48] GRAVES DISEASE
    GREER, MA
    ANNUAL REVIEW OF MEDICINE, 1964, 15 : 65 - &
  • [49] Graves' disease
    Ferrer, Elisa
    Moral, Ma Angels
    DRUGS OF THE FUTURE, 2007, 32 (06) : 555 - 561
  • [50] Graves' disease
    Rotondi, Mario
    Fonte, Rodolfo
    Chiovato, Luca
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13): : 1407 - 1408